Long-term follow-up post hoc analysis of sorafenib maintenance therapy after allo-HSCT in patients with FLT3-mutated AML

Approximately 25% of adults with acute myeloid leukemia (AML) have FLT3 internal tandem duplication (FLT3-ITD) mutations, which are associated with poor survival outcomes.¹ Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can improve survival in these patients. However, FLT3-ITD mutations are associated with increased risk of relapse. Sorafenib is a multi-kinase FLT3-ITD inhibitor that has demonstrated improved relapse rates when used as a maintenance therapy in patients with FLT3-ITD AML after allo-HSCT. The SORMAIN trial, previously reported by the AML Hub, demonstrated a 2-year overall survival (OS) of 90.5% with sorafenib maintenance versus 66.2% with placebo (p = 0.007). However, there are limited data on long-term follow-up of sorafenib maintenance.

The 5-year follow-up results of a phase III trial investigating the use of sorafenib maintenance post-transplantation in patients with FLT3-mutated AML were recently published by Xuan et al. in The Lancet.¹ We are pleased to present a summary of this post hoc long-term analysis here.

Study design

This post hoc analysis was of a multicenter, open-label, randomized trial (NCT02474290) in China. Patients with FLT3-ITD AML undergoing first allo-HSCT were eligible. The study design is shown in Figure 1.

For this long-term analysis, the 5-year endpoints were as follows:

• OS – time from transplantation until death from any cause
• Cumulative incidence of relapse
• Non-relapse mortality (NRM) – death from any cause not subsequent to relapse
• Leukemia-free survival (LFS) – time from transplantation until relapse or death from any cause
• Graft-versus-host-disease (GvHD)-free, relapse-free survival (GRFS) – time from transplantation until Grade 2–4 acute GvHD, chronic GvHD (cGvHD) requiring systemic immunosuppressive therapy, relapse, or death from any cause
• Cumulative incidence of cGvHD
• Late effects – evaluated in patients who were leukemia free for at least 6 months after transplantation

Results

A total of 202 patients were included, 100 in sorafenib maintenance and 102 patients in the control arm, and median follow-up was 60.4 months. Sorafenib maintenance showed improved OS, LFS, and GRFS versus control arm (Figure 2). The median LFS was not reached in the sorafenib maintenance arm versus 35.8 months in the control arm.

Relapse

• The median time to relapse after transplantation was 11.9 versus 6.5 months in the sorafenib and control arms, respectively (p = 0.25).
• Relapse occurred in 15% and 36% of patients in the sorafenib maintenance and control arms, respectively.
• Of these patients, relapse after transplantation occurred at:
  • 12–24 months in 53% (8/15) of patients in the sorafenib maintenance arm
  • 6 months in 46% (17/37) of patients in control arm.
• Of the 15 patients who relapsed in the sorafenib group, three patients relapsed within 6 months of stopping treatment. The median time to relapse was 5.6 months after stopping sorafenib.
  • These patients had measurable residual disease (MRD)-positive status at transplantation and were MRD negative at Day 180 after transplantation.
• At 18 months after stopping sorafenib, 73% (11/15) of patients in the sorafenib maintenance arm relapsed.
  • Of these 64% (7/11) of patients were MRD-positive at transplantation.
• The remaining patient relapsed at 25.3 months after stopping sorafenib.

Risk factors of survival and relapse

• A total of 73 patients died: 28 were on sorafenib maintenance and 45 were in the control arm (Figure 3).
• Multivariable analysis showed that sorafenib maintenance after transplantation (hazard ratio [HR], 0.52; 95% confidence interval [CI], 0.32–0.85; p = 0.0087) and cGvHD (HR, 0.50; 95% CI, 0.31–0.80; p = 0.0044) were protective factors associated with OS.
• The only risk factor associated with OS was the MRD status at transplantation (positive vs negative) (HR, 1.76; 95% CI, 0.97–3.21; p = 0.064).

Genetic subgroup analysis

A total of 71% of all patients harbored at least one co-occurring mutation. The most common co-occurring mutations (in ≥5% of patients) included NPM1 (27%), DNMT3A (15%), TET2 (11%), CEBPA (11%), IDH2 (7%), and RUNX1 (6%). Triple mutations (NPM1, DNMT3A, and FLT3-ITD) occurred in 10% of patients. Of the 15% and 36% of patients who relapsed in the sorafenib maintenance and control arms, 40% and 49% had FLT3-mutated AML, respectively. Figure 4 shows OS, cumulative incidence of relapse, and LFS at 5 years in the genetic subgroups in sorafenib maintenance and control arms.

Chronic GvHD and late effects

A total of 53% of patients developed cGvHD: 54% in the sorafenib maintenance and 51% in the control arm (Figure 5).

Late effects were analyzed in 174 patients who were leukemia-free for ≥6 months post-transplant, 55% of these were in sorafenib maintenance and 45% in the control arm (Figure 6).

Conclusion

This long-term follow-up study demonstrated the benefits of sorafenib maintenance in patients with FLT3-mutated AML undergoing allo-HSCT. It shows that OS, LFS, and GRFS were greatly improved, leading to long-term survival in this population. The authors commented that 5 years was the longest duration of follow-up for sorafenib maintenance in patients with FLT3-mutated AML in a transplant setting. However, the study’s limitations should be considered when interpreting the findings. This study was an extension of a post hoc analyses with small sample sizes in some subgroups. The study included patients younger than 60 years who received myeloablative conditioning, limiting the generalizability of the findings.